Novavax to Expand its Maryland Sites to Accommodate Rapid Company Growth

November 3, 2020
BioPharm International Editors

In the wake of its efforts to develop a COVID-19 vaccine candidate, the company has secured two additional properties in the Gaithersburg, MD area.

Novavax announced on Nov. 2, 2020 that it is expanding its Gaithersburg, MD site to accommodate the company’s rapid growth in the wake of its efforts to develop a COVID-19 vaccine candidate.

According to a company press release, Novavax has secured two additional properties in the Gaithersburg area, a 122,000 ft2 space for manufacturing, research and development, and offices, and a 9.7-acre parcel of land for future accommodations. The company plans to invest in the buildout of the sites for use in early 2021.

Currently, Novavax is conducting a Phase III trial for its COVID-19 vaccine candidate, NVX-CoV2373, in the United Kingdom, with plans to conduct additional trials in the United States and Mexico in November, the press release said.

“The expansion of our physical footprint reflects Novavax’ significant growth as we work to both rapidly deliver a COVID-19 vaccine and progress NanoFlu, our influenza vaccine candidate, for regulatory submission and potential commercialization,” said Stanley C. Erck, president and CEO, Novavax, in the press release. “We appreciate the support, partnership, and speed of the Maryland Department of Commerce, Montgomery County, and the city of Gaithersburg, which have enabled the expansion of our operations, enhanced our ability to retain and attract highly skilled employees, and reinforced our longstanding commitment to the biotechnology sector in Maryland.”

Source: Novavax